Director/PDMR Shareholding

Director/PDMR Shareholding March 3, 2015 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces itwas notified today that on February 28, 2015, Performance Share Awards ("PSAs")granted to Persons Discharging Managerial Responsibilities ("PDMRs") under PartB of the Shire Portfolio Share Plan ("PSP") vested. The number of AmericanDepositary Shares ("ADSs") released and sold on March 2, 2015, were as follows: PDMR ADSs Released(1) ADSs Sold(2) Mark Enyedy 268 89 Jeffrey Poulton 1,679 554 Philip Vickers 961 317 1. The number of ADSs released reflects the aggregate part-vesting, on February 28, 2015, of awards granted on an annual basis from February 28, 2012, to February 28, 2014, which vest in tranches over a three-year period. In accordance with the PSP rules, the vested PSAs have been increased to reflect dividends paid by the Company during the period from the respective dates of grant to the date of part-vesting. 2. ADSs were sold to satisfy personal tax liabilities. The sale of ADSs took place on the NASDAQ at an average sale price of $237.0889 each. The Company also announces that it was notified today that deferred ADSsgranted to Flemming Ornskov, MD, MPH, Chief Executive Officer, on May 2, 2013,vested on February 28, 2015, in accordance with the terms of his employmentagreement. The grant of deferred ADSs constituted part of the replacementpayment paid to Dr. Ornskov as compensation for bonuses forfeited in connectionwith the termination of his prior employment. The number of ADSs released andsold on March 2, 2015, were as follows: ADSs Released ADSs Sold(3) 15,286 7,288 3. ADSs were sold to satisfy Dr. Ornskov's personal tax liability. The sale of ADSs took place on the NASDAQ at an average sale price of $236.0836 each. One ADS is equal to three Ordinary Shares of 5 pence each. This notification is to satisfy the Company's obligations under 3.1.4(R)(1)(a)of the Disclosure and Transparency Rules. Tony Guthrie Deputy Company Secretary For further information please contact: Investor RelationsSarah Elton-Farr [email protected] +44 1256 894157 NOTES TO EDITORS Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and marketing innovative specialtymedicines to meet significant unmet patient needs. We focus on providing treatments in Rare Diseases, Neuroscience,Gastrointestinal and Internal Medicine and we are developing treatments forsymptomatic conditions treated by specialist physicians in other targetedtherapeutic areas, such as Ophthalmics.